Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00950794
Other study ID # 112376
Secondary ID
Status Completed
Phase Phase 4
First received July 30, 2009
Last updated August 6, 2009
Start date September 2003
Est. completion date February 2005

Study information

Verified date August 2009
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

To demonstrate the efficacy (non-inferiority) of Salmeterol 50mcg bid (100mcg/day), compared with Hokunalin (tulobuterol) tape 2mg once a day, in terms of improvement in pulmonary function (peak expiratory flow: PEF) in a randomized, double-blind, parallel-group comparative study in adult patients with bronchial asthma on ICS 400mcg/day of FP equivalent.


Description:

Primary To demonstrate the efficacy (non-inferiority) of Salmeterol 50mcg bid (100mcg/day), compared with Hokunalin (tulobuterol) tape 2mg once a day, in terms of improvement in pulmonary function (peak expiratory flow: PEF) in a randomized, double-blind, parallel-group comparative study in adult patients with bronchial asthma on ICS 400mcg/day of FP equivalent.

Secondary

- To evaluate the efficacy of Salmeterol , compared with Hokunalin (tulobuterol) tape in terms of asthma symptoms recorded in the asthma diary.

- To evaluate the safety of Serevent compared with Hokunalin (tulobuterol) tape.


Recruitment information / eligibility

Status Completed
Enrollment 367
Est. completion date February 2005
Est. primary completion date February 2005
Accepts healthy volunteers No
Gender Both
Age group 15 Years and older
Eligibility Inclusion Criteria:

- For entry into run-in period (Visit 1)

A subject will be considered eligible for inclusion in this study only if all of the following criteria apply:

1. Males or females aged >= 15 years at the time of giving informed consent.

2. Subjects who are able to give a written informed consent to participation in the study.

However, if a subject is aged < 20 years at the time of giving informed consent, a written informed consent should be obtained from the subject and his/her legally acceptable representative.

3. Outpatients.

4. Subjects who had been diagnosed as asthma at least 6 months prior to Visit 1.

5. Subjects who have been receiving ICS 400mcg/day of FP equivalent for at least 8 weeks prior to Visit 1.

- For entry into the treatment period (Visit 2)

A subject will be considered eligible for entering the treatment period only if he/she completes the run-in period and meets all of the following criteria:

1. Subjects who meet both of the following criteria in terms of pulmonary function.

- Has a mean morning PEF during the last 7 days (at least 4 days) prior to Visit 2 is >= 40% of the predicted value.

- Has at least 2 days with a diurnal variation in PEF of >= 15% during the run-in period, or had been confirmed and recorded reversibility of >= 15% using rapid-acting inhaled beta2 agonists within 3 months prior to Visit 1 (including Visit 1).

2. Subjects who have >= 70 % compliance with asthma medication during the run-in period.

3. Subjects who were able to measure peak flows correctly during the run-in period, in the investigator's/subinvestigator's judgment.

4. Subjects who were able to keep the asthma diary correctly during the run-in period, in the investigator's/subinvestigator's judgment.

Exclusion Criteria:

- A subject will not be eligible for inclusion in this study if any of the following criteria apply at Visit 1 or Visit 2:

1. Subjects who have received injected steroids, injected ACTH, or oral steroids within four weeks of Visit1 or during run-in period.

2. Subjects who have received xanthines (oral, injected, suppository), beta2 agonists other than rescue medication (rapid-acting inhaled beta2 agonists), or inhaled anti-cholinergics during the run-in period.

3. Subjects with respiratory disease other than asthma (e.g., chronic bronchitis, emphysema, bronchiectasis, pulmonary fibrosis, lung cancer, sarcoidosis, and old tuberculosis) which, in the judgment of the investigator/subinvestigator, are likely to affect efficacy evaluation.

4. Subjects with uncontrollable diabetes mellitus, hypertension, heart disease, or hyperthyroidism, who are inappropriate for this study in the judgement of the investigator/sub investigator.

5. Subjects who are unsuitable for this study in the judgment of the investigator/subinvestigator based on 12-lead ECG findings at Visit 1.

6. Subjects who are regularly using medications containing the following ingredients:

beta-blockers, alpha/beta-blockers

7. Subjects who have received immunosuppressive medications excluding Tacrolimus ointment.

8. Subjects who are receiving catecholamines.

9. Subjects with atopic dermatitis who are inappropriate for this study in the judgment of the investigator/subinvestigator.

10. Subjects who had or are suspected to have had hypersensitivity to any of the investigational products.

11. Subjects who received the last dose of other investigational drugs in the past 30 days.

12. Subject who are currently pregnant, possibly pregnant, lactating or willing to become pregnant during the study period.

13. Subjects who consume alcohol or drugs excessively the opinion of the investigator/subinvestigator.

14. Subjects who are judged by the investigator/subinvestigator to have Step 4 asthma (severe persistent), referring to "GINA2002" and "J-GL2003".

15. Subjects who are judged by the investigator/subinvestigator to be inappropriate for this study for any other reasons.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Salmeterol(SN408D)
Salmeterol(SN408D):long-acting Beta2-agonist
Hokunalin (tulobuterol) tape
Hokunalin (tulobuterol) tape:long-acting Beta2-agonist

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Outcome

Type Measure Description Time frame Safety issue
Primary Change in morning PEF 8 week No
Secondary Use of short acting beta agonist 8 week No
Secondary Adverse event 8 week Yes
Secondary Evening PEF 8 week No
Secondary Symptom score 8 week No
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device